Passion and purpose to transform patient journeys in anxiety and depression.

Joanne Curley, Ph.D. joined our Board of Directors and Board’s Corporate Governance and Nominating Committee in April 2021. Dr. Curley brings more than 25 years of experience in the development and commercialization of pharmaceutical products, including R&D governance. She is currently the Chief Development Officer at Vera Therapeutics, Inc. Prior to joining Vera, Dr. Curley spent 15 years with Gilead Sciences, Inc., during which time the anti-viral portfolio grew from four to seventeen commercial products. While at Gilead, Dr. Curley led Project and Portfolio Management with oversight of the development pipeline across four therapeutic areas and was responsible for research and development governance. Before Gilead, Dr. Curley worked as an aerosol formulation scientist and subsequently as a project leader at Nektar Therapeutics. She received a BSc in Physics and Chemistry from Trinity College, Ireland, a Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst and completed a post-doctorate at Massachusetts Institute of Technology and Harvard Medical School, focused on long-acting biodegradable formulations.